Immunotherapy in prostate cancer: challenges and opportunities

Immunotherapy ◽  
2016 ◽  
Vol 8 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Masanori Noguchi ◽  
Noriko Koga ◽  
Fukuko Moriya ◽  
Kyogo Itoh
Keyword(s):  
Prostate Cancer ◽  
Challenges And Opportunities

scholarly journals Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research

2019 ◽  
Vol 30 (5) ◽  
pp. 443-456 ◽  
Author(s):  
Adolfo G. Cuevas ◽  
Claudia Trudel-Fitzgerald ◽  
Leslie Cofie ◽  
Masayoshi Zaitsu ◽  
Jennifer Allen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Disparities ◽  
Future Research ◽  
Challenges And Opportunities

scholarly journals Convergence of immunotherapy, radiotherapy and prostate cancer: challenges and opportunities

Immunotherapy ◽  
2017 ◽  
Vol 9 (9) ◽  
pp. 695-699
Author(s):  
Michael Green ◽  
Felix Y Feng ◽  
Rohit Mehra ◽  
Daniel E Spratt
Keyword(s):  
Prostate Cancer ◽  
Challenges And Opportunities

Epigenetic Editing in Prostate Cancer: Challenges and Opportunities

Epigenetics ◽  
2021 ◽  
pp. 1-25
Author(s):  
Mariana Brütt Pacheco ◽  
Vânia Camilo ◽  
Rui Henrique ◽  
Carmen Jerónimo
Keyword(s):  
Prostate Cancer ◽  
Challenges And Opportunities ◽  
Epigenetic Editing

scholarly journals PSMA Theranostics: Current Status and Future Directions

2018 ◽  
Vol 17 ◽  
pp. 153601211877606 ◽  
Author(s):  
Kambiz Rahbar ◽  
Ali Afshar-Oromieh ◽  
Hossein Jadvar ◽  
Hojjat Ahmadzadehfar
Keyword(s):  
Prostate Cancer ◽  
Current Status ◽  
Castration Resistant Prostate Cancer ◽  
Future Directions ◽  
Castration Resistant ◽  
Promising Target ◽  
Challenges And Opportunities ◽  
Low Toxicity ◽  
Patient Selection Criteria ◽  
Specific Membrane

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT. Challenges and opportunities of PSMA theranostics are discussed.

Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer

2003 ◽  
Vol 21 (1) ◽  
pp. 73-78 ◽  
Author(s):  
Ian M Thompson ◽  
Joseph A Basler ◽  
Robin Leach ◽  
Dean Troyer ◽  
Eric Klein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Design And Implementation ◽  
Challenges And Opportunities
Sign in / Sign up

Export Citation Format

Share Document